reports
Aeterna Zentaris and Ceapro Complete Merger Transaction
Aeterna Zentaris and Ceapro Complete Merger Transaction TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and closing of their all-stock merger of equals transaction (the “Transaction”), which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023. “This is an important day for shareholders of ...
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provi...
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update – Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,000 in Q1 2023 – Announced approval by shareholders of merger of equals with Aeterna Zentaris to create a diversified biopharmaceutical company; expected to close in the second quarter of 2024, subject to the closing conditions EDMONTON, Alberta, ...
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights – 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Sales impacted (decreased by 49% from $18.8M in 2022 to $9.6M in 2023) due to re-organization associated with the spin-off of the consumer division of one major customer – Announced merger of equals with Aeterna Zentaris ...
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate completing the Transaction i...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Spec...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows: Aeterna shareholders approved the Transaction with the following voting...
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentari...
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.”ISS states in its Ceapro FOR recommendation that “The arrangement is the result of arm's length negotiations between the partie...
Ceapro Provides Business Update on Progress of Ongoing Development Pro...
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the Company announced it entered into a definitive agreement to combine operations with Aeterna Zentaris Inc. (“Aeterna Zentaris”), a TSX and Nasdaq listed specialty biopharmaceutical company, in an all-stock merger of equals transaction to be effected by way of a plan of...
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection W...
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro” or the “Company”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting materials (collectively, the “Meeting Materials”) for the special meeting (the “Meeting”) of Securityholders (as defined below) to be held on March 12, 2024, called to consider, among other thi...
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Ass...
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases – Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute – No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the com...
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Result...
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights – Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot scale units – Q3 2023 sales of $2,619,000 vs $3,845,000 in Q3 2022; YTD sales of $7,983,000 vs $15,517,000 – Ended the quarter with $11.4 million in cash allowing funding for planned pipeline and technology developments EDMONTON, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- (TSX-V: ...
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product ...
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and activity of avenanthramides in managing conditions related to inflammation EDMONTON, Alberta, Nov. 27, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and ...
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstech...
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in AustriaYeast beta glucan (YBG) to be the first bio active to be processed at this location EDMONTON, Alberta, Nov. 07, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of ac...
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Result...
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update - $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization - Ended the quarter with $11.3 million in cash allowing funding for planned pipeline and technology developments - Ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq ...
Ceapro Extends Exclusive International Supply and Distribution Agreeme...
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise – Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market – Offering of new preservative free dry product formulation for oat beta glucan EDMONTON, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the devel...
Ceapro Announces Next Phase of Research Collaboration with the Angioge...
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation – New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct research on characte...
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
Ceapro to Participate in the Virtual Investor Summer Spotlight Series Live moderated video webcast on Wednesday, July 12th at 1:00 PM ET EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that of Ceapro and of the Angiogenesis Foundation will participate in the on Wednesday, July 12, 2023 at 1:00 PM ET. A of the presentation will be available on the page of the ...
Ceapro Announces Results of 2023 Shareholders’ Meeting
Ceapro Announces Results of 2023 Shareholders’ Meeting EDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 6, 2023 as per the following results: NomineeVotes ForVotes Against% of votes cast ...
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provi...
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update – Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended Mar...
Ceapro Inc. Presents Encouraging Results from Research Collaboration S...
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases – Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference – – Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models – – Company advancing toward go/no-go milestone for further e...
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Gluc...
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration – Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration – Tissue treated with Avenanthramides (“AVE”) and oat beta glucan (“BG”) bioactives healed to become more normal skin as compared to untreated scar tissue EDMONTON, Alberta, May 03, 2023 (GLOBE NEWSWIRE) -- (TSX-V: ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.